title: Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.
abstract: The detection of prostate cancer lesions by PET imaging of the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during the last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which has recently demonstrated its suitability in individual first-in-man studies. The radiometal chelator HBED-CC used in this molecule represents a rather rarely used acyclic complexing agent with chemical characteristics favourably influencing the biological functionality of the PSMA inhibitor. The simple replacement of HBED-CC by the prominent radiometal chelator DOTA was shown to dramatically reduce the in vivo imaging quality of the respective 68Ga-labelled PSMA-targeted tracer proving that HBED-CC contributes intrinsically to the PSMA binding of the Glu-urea-Lys(Ahx) pharmacophore. Owing to the obvious growing clinical impact, this work aims to reflect the properties of HBED-CC as acyclic radiometal chelator and presents novel preclinical data and relevant aspects of the radiopharmaceutical production process of [68Ga]Ga-PSMA-HBED-CC.
authors.affiliation: German Cancer Research Center (dkfz), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, Heidelberg 69120, Germany. m.eder@dkfz.de.
authors.forename: Matthias
authors.initials: M
authors.lastname: Eder
authors.affiliation: German Cancer Research Center (dkfz), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, Heidelberg 69120, Germany. o.neels@dkfz.de.
authors.forename: Oliver
authors.initials: O
authors.lastname: Neels
authors.affiliation: German Cancer Research Center (dkfz), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, Heidelberg 69120, Germany. miriam.mueller@wak-gmbh.de.
authors.forename: Miriam
authors.initials: M
authors.lastname: Müller
authors.affiliation: German Cancer Research Center (dkfz), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, Heidelberg 69120, Germany. u.bauder-wuest@dkfz.de.
authors.forename: Ulrike
authors.initials: U
authors.lastname: Bauder-Wüst
authors.affiliation: German Cancer Research Center (dkfz), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, Heidelberg 69120, Germany. y.remde@dkfz.de.
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Remde
authors.affiliation: German Cancer Research Center (dkfz), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, Heidelberg 69120, Germany. martin.schaefer@dkfz.de.
authors.forename: Martin
authors.initials: M
authors.lastname: Schäfer
authors.affiliation: German Cancer Research Center (dkfz), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, Heidelberg 69120, Germany. u.hennrich@dkfz.de.
authors.forename: Ute
authors.initials: U
authors.lastname: Hennrich
authors.affiliation: German Cancer Research Center (dkfz), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, Heidelberg 69120, Germany. m.eisenhut@dkfz.de.
authors.forename: Michael
authors.initials: M
authors.lastname: Eisenhut
authors.affiliation: Department of Nuclear Medicine, University of Heidelberg, Im Neuenheimer Feld 400, Heidelberg 69120, Germany. Ali.Afshar@med.uni-heidelberg.de.
authors.forename: Ali
authors.initials: A
authors.lastname: Afshar-Oromieh
authors.affiliation: Department of Nuclear Medicine, University of Heidelberg, Im Neuenheimer Feld 400, Heidelberg 69120, Germany. Uwe.Haberkorn@med.uni-heidelberg.de.
authors.forename: Uwe
authors.initials: U
authors.lastname: Haberkorn
authors.affiliation: German Cancer Research Center (dkfz), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, Heidelberg 69120, Germany. k.kopka@dkfz.de.
authors.forename: Klaus
authors.initials: K
authors.lastname: Kopka